最新出版物
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
Int J Cancer. 2019 Mar 1;144
Cortesi L, Canossi B, Battista R, Pecchi A, Drago A, Dal Molin C, Toss A, De Matteis E, Marchi I, Torricelli P, Cascinu S.
扩展阅读
GISCAD investigators Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Eur J Cancer. 2017 Sep;83:106-115.
Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F
扩展阅读
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain.
Journal of Clinical Oncology 2016; 34: 436–42
Bandieri E, Romero M, Ripamonti CI, et al.
扩展阅读
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes.
Pancreatology 2015; 15: 8–12
Hidalgo M, Cascinu S, Kleeff J, et al
扩展阅读
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, noninferiority phase 3 study.
The Lancet Oncology 2014; 15:
Price TJ, Peeters M, Kim TW, et al
扩展阅读
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Journal of Clinical Oncology 2011; 29: 2011–9
Van Cutsem E, Köhne C-H, Láng I, et al
扩展阅读
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
Journal of Clinical Oncology 2009; 27: 2622–9
Loupakis F, Pollina L, Stasi I, et al.
扩展阅读
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer:a randomised, multicentre, phase II trial.
The Lancet Oncology 2008; 9: 39–44
Cascinu S, Berardi R, Labianca R, et al.
扩展阅读
Nuclear factorkB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Journal of Clinical Oncology 2007; 25: 3930–5
Scartozzi M, Bearzi I, Pierantoni C, et al
扩展阅读
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
Journal of Clinical Oncology 2006; 24: 1883–91
Ruzzo A, Graziano F, Kawakami K, et al.
扩展阅读
Prognostic role of interleukin-1ß gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer.
Journal of Clinical Oncology 2005; 23: 2339–45
Graziano F, Ruzzo A, Santini D, et al
扩展阅读
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies.
Journal of Clinical Oncology 2004; 22: 4720–6
Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S.
扩展阅读
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer.
Oncogene 2002; 21: 8192–5
Humar B, Graziano F, Cascinu S, et al.
扩展阅读
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial.
Journal of Clinical Oncology 1995; 13: 26–32
Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G.
扩展阅读
Recombinant human erythropoietin treatment in cisplatinassociated anemia: A randomized, double-blind trial with placebo.
Journal of Clinical Oncology 1994; 12: 1058–62
Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G.
扩展阅读
